405 related articles for article (PubMed ID: 28038705)
41. The spectrum of nodular lymphocyte predominant Hodgkin lymphoma: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology.
Hartmann S; Dojcinov S; Dotlic S; Gibson SE; Hsi ED; Klapper W; Klimkowska M; Pinilla SMR; Richter J; Sabattini E; Tousseyn T; de Jong D
Virchows Arch; 2023 Oct; 483(4):451-463. PubMed ID: 37530790
[TBL] [Abstract][Full Text] [Related]
42. Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations.
Agaimy A; Wild V; Märkl B; Wachter DL; Hartmann A; Rosenwald A; Ihrler S
Am J Surg Pathol; 2015 Sep; 39(9):1206-12. PubMed ID: 25929348
[TBL] [Abstract][Full Text] [Related]
43. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: a study of six cases concurrently involving the same site.
Cotta CV; Coleman JF; Li S; Hsi ED
Histopathology; 2011 Dec; 59(6):1194-203. PubMed ID: 22175899
[TBL] [Abstract][Full Text] [Related]
44. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma.
Wu D; Thomas A; Fromm JR
Cytometry B Clin Cytom; 2016 Sep; 90(5):424-32. PubMed ID: 26084540
[TBL] [Abstract][Full Text] [Related]
45. A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.
Schuhmacher B; Rengstl B; Döring C; Bein J; Newrzela S; Brunnberg U; Kvasnicka HM; Vornanen M; Küppers R; Hansmann ML; Hartmann S
Oncotarget; 2016 Nov; 7(44):72197-72210. PubMed ID: 27708232
[TBL] [Abstract][Full Text] [Related]
46. Flow Cytometric Detection of the Double-Positive (CD4+CD8+)/PD-1bright T-Cell Subset Is Useful in Diagnosing Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
Chen ZW; Wizniak J; Shang C; Lai R
Arch Pathol Lab Med; 2022 Jun; 146(6):718-726. PubMed ID: 34506624
[TBL] [Abstract][Full Text] [Related]
47. Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience.
Uherova P; Valdez R; Ross CW; Schnitzer B; Finn WG
Am J Clin Pathol; 2003 Feb; 119(2):192-8. PubMed ID: 12579988
[TBL] [Abstract][Full Text] [Related]
48. Diagnostic Utility of Flow Cytometry Analysis of Reactive T Cells in Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
David JA; Huang JZ
Am J Clin Pathol; 2016 Jan; 145(1):107-15. PubMed ID: 26712878
[TBL] [Abstract][Full Text] [Related]
49. Mantle cell lymphoma--a spectrum from indolent to aggressive disease.
Sander B; Quintanilla-Martinez L; Ott G; Xerri L; Kuzu I; Chan JK; Swerdlow SH; Campo E
Virchows Arch; 2016 Mar; 468(3):245-57. PubMed ID: 26298543
[TBL] [Abstract][Full Text] [Related]
50. Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma.
Bacher U; Kern W; Haferlach C; Alpermann T; Haferlach T; Schnittger S
Exp Hematol; 2013 Dec; 41(12):1028-37. PubMed ID: 24060591
[TBL] [Abstract][Full Text] [Related]
51. A subset of CD5- diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus.
Ehinger M; Linderoth J; Christensson B; Sander B; Cavallin-Ståhl E
Am J Clin Pathol; 2008 Apr; 129(4):630-8. PubMed ID: 18343791
[TBL] [Abstract][Full Text] [Related]
52. Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2.
Chuang SS; Huang WT; Hsieh PP; Tseng HH; Campo E; Colomer D; Ye H; Lu CL; Chang HM; Cho CY; Huang SH; Lu YC; Wu JD
Pathol Int; 2006 Aug; 56(8):440-8. PubMed ID: 16872438
[TBL] [Abstract][Full Text] [Related]
53. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation.
Fan Z; Natkunam Y; Bair E; Tibshirani R; Warnke RA
Am J Surg Pathol; 2003 Oct; 27(10):1346-56. PubMed ID: 14508396
[TBL] [Abstract][Full Text] [Related]
54. Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Spinner MA; Varma G; Advani RH
Br J Haematol; 2019 Jan; 184(1):17-29. PubMed ID: 30485408
[TBL] [Abstract][Full Text] [Related]
55. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
[TBL] [Abstract][Full Text] [Related]
56. CD5(-) diffuse large B-cell lymphoma with peculiar cyclin D1+ phenotype. Pathologic and molecular characterization of a single case.
Lucioni M; Novara F; Riboni R; Fiandrino G; Nicola M; Kindl S; Boveri E; Jemos V; Arcaini L; Zuffardi O; Paulli M
Hum Pathol; 2011 Aug; 42(8):1204-8. PubMed ID: 21334716
[TBL] [Abstract][Full Text] [Related]
57. Immunophenotypic Characterization and Purification of Neoplastic Cells from Lymph Nodes Involved by T-Cell/Histiocyte-rich Large B-cell Lymphoma by Flow Cytometry and Flow Cytometric Cell Sorting.
Glynn E; Fromm JR
Cytometry B Clin Cytom; 2020 Jan; 98(1):88-98. PubMed ID: 31254446
[TBL] [Abstract][Full Text] [Related]
58. The expression of SOX11, cyclin D1, cyclin D2, and cyclin D3 in B-cell lymphocytic proliferative diseases.
Cao X; Fan L; Fang C; Zhu DX; Dong HJ; Wang DM; Wang YH; Xu W; Li JY
Med Oncol; 2012 Jun; 29(2):1190-6. PubMed ID: 21479697
[TBL] [Abstract][Full Text] [Related]
59. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/cyclin D1 gene rearrangements.
Swerdlow SH; Zukerberg LR; Yang WI; Harris NL; Williams ME
Am J Surg Pathol; 1996 May; 20(5):627-40. PubMed ID: 8619427
[TBL] [Abstract][Full Text] [Related]
60. Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma.
Wlodarska I; Meeus P; Stul M; Thienpont L; Wouters E; Marcelis L; Demuynck H; Rummens JL; Madoe V; Hagemeijer A
Leukemia; 2004 Oct; 18(10):1705-10. PubMed ID: 15306823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
